Literature DB >> 34851726

Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.

Jill Blumenthal1, Raphael Landovitz2, Sonia Jain3, Feng He3, Ryan Kofron2, Eric Ellorin1, Gifty M Ntim2, Jamila K Stockman1, Katya Corado4, K Rivet Amico5, David J Moore6, Sheldon Morris1.   

Abstract

Little information is known about the cisgender women who seek and initiate pre-exposure prophylaxis (PrEP) for HIV prevention in the United States. Adherence Enhancement Guided by Individualized Texting and Drug Levels was a 48-week single-arm open-label demonstration study of daily oral tenofovir disoproxil fumaratel emtricitabine (TDF/FTC) in cisgender women ≥ 18 years old at risk for HIV. Participants were surveyed at screening and enrollment about sociodemographics, HIV risk perception and behaviors, and PrEP perspectives and aggregated into three risk groups according to HIV sexual risk behavior: being in a serodiscordant partnership (SD), engaging in sex work (SW), and having partners with unknown HIV status at risk for HIV (UP). One hundred sixty-seven women presented for screening with n = 31 screen failures. Of the 162 women completing enrollment, mean age was 40 (standard deviation 11), with 41% non-Hispanic Black, 22% non-Hispanic White, and 19% Latina. Compared with those who screened ineligible, enrolled participants were more likely to have heard of PrEP, had higher HIV risk perception, and reported higher perceived PrEP efficacy. Sixty-four women (47%) were categorized as SD, 21 (15%) as SW, and 51 (38%) as UP. The SW were more likely to report higher levels of drinking and drug use (p = 0.002) and history of intimate partner violence in the past year (p < 0.001) compared with SD and UP. Among cisgender women enrolled, there were significant differences between the three risk groups by demographics, HIV risk behavior, and PrEP perspectives, suggesting that interventions to successfully implement PrEP in US women may need to be tailored by HIV risk group. Clinical Trial Registration number: NCT02584140.

Entities:  

Keywords:  HIV prevention; cisgender women; pre-exposure prophylaxis (PrEP); risk behaviors

Mesh:

Substances:

Year:  2021        PMID: 34851726      PMCID: PMC8905235          DOI: 10.1089/apc.2021.0114

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.944


  32 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

3.  Targeted Screening for HIV Pre-Exposure Prophylaxis Eligibility in Two Emergency Departments in Washington, DC.

Authors:  Paige Kulie; Amanda D Castel; Zhaonian Zheng; Natasha N Powell; Aneil Srivastava; Sandhya Chandar; Melissa L McCarthy
Journal:  AIDS Patient Care STDS       Date:  2020-12       Impact factor: 5.078

4.  Critical consciousness, racial and gender discrimination, and HIV disease markers in African American women with HIV.

Authors:  Gwendolyn A Kelso; Mardge H Cohen; Kathleen M Weber; Sannisha K Dale; Ruth C Cruise; Leslie R Brody
Journal:  AIDS Behav       Date:  2014-07

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.

Authors:  Dawn K Smith; Michelle Van Handel; Richard J Wolitski; Jo Ellen Stryker; H Irene Hall; Joseph Prejean; Linda J Koenig; Linda A Valleroy
Journal:  J Miss State Med Assoc       Date:  2015-12

7.  Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients.

Authors:  Danielle B Garfinkel; Kamila A Alexander; Reagan McDonald-Mosley; Tiara C Willie; Michele R Decker
Journal:  AIDS Care       Date:  2016-09-29

8.  Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.

Authors:  Roy M Gulick; Timothy J Wilkin; Ying Q Chen; Raphael J Landovitz; K Rivet Amico; Alicia M Young; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Ian McGowan; Leslie M Cottle; Adriana Andrade; Cheryl Marcus; Karin L Klingman; Wairimu Chege; Alex R Rinehart; James F Rooney; Philip Andrew; Robert A Salata; Marc Siegel; Yukari C Manabe; Ian Frank; Ken Ho; Jorge Santana; Joanne D Stekler; Shobha Swaminathan; Marybeth McCauley; Sally Hodder; Kenneth H Mayer
Journal:  Ann Intern Med       Date:  2017-08-22       Impact factor: 25.391

9.  Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Authors:  Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Jan van Lunzen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; David Asboe; Pompeyo Viciana; Félix Gutiérrez; Bonaventura Clotet; Christian Pradier; Jan Gerstoft; Rainer Weber; Katarina Westling; Gilles Wandeler; Jan M Prins; Armin Rieger; Marcel Stoeckle; Tim Kümmerle; Teresa Bini; Adriana Ammassari; Richard Gilson; Ivanka Krznaric; Matti Ristola; Robert Zangerle; Pia Handberg; Antonio Antela; Sris Allan; Andrew N Phillips; Jens Lundgren
Journal:  JAMA       Date:  2016-07-12       Impact factor: 56.272

Review 10.  Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States.

Authors:  Erika Aaron; Cori Blum; Dominika Seidman; Mary Jo Hoyt; Joanne Simone; Meg Sullivan; Dawn K Smith
Journal:  AIDS Patient Care STDS       Date:  2018-01       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.